What OrganaBio’s Excellos asset acquisition reveals about next-generation CDMO demand
Cell therapy needs redundancy, not just cleanrooms. OrganaBio’s Excellos deal tests whether bicoastal CDMO scale can reduce developer risk.
Why Vetter’s Saarlouis expansion matters for sterile injectable supply chains
Injectable capacity is tightening. Vetter’s Saarlouis bet shows why Europe wants more control over sterile drug manufacturing.
Why Forma Life Sciences’ U.S. CDMO launch signals renewed momentum in domestic oral solid drug manufacturing
Forma Life Sciences launches a U.S. CDMO focused on oral solid drug manufacturing. Discover what the move means for pharma supply chains and drug development.